Dimensional Fund Advisors LP Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

Dimensional Fund Advisors LP bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 14,054 shares of the company's stock, valued at approximately $1,080,000. Dimensional Fund Advisors LP owned 0.05% of GeneDx as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. MCF Advisors LLC raised its stake in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after purchasing an additional 182 shares during the period. Sterling Capital Management LLC raised its stake in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after purchasing an additional 316 shares during the period. Global Retirement Partners LLC purchased a new position in GeneDx during the fourth quarter worth about $28,000. KLP Kapitalforvaltning AS purchased a new position in GeneDx during the fourth quarter worth about $200,000. Finally, Evolution Wealth Advisors LLC purchased a new position in GeneDx during the fourth quarter worth about $202,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Performance

GeneDx stock traded up $2.71 during trading hours on Monday, reaching $71.02. 1,640,880 shares of the stock were exchanged, compared to its average volume of 757,598. The stock has a market cap of $2.03 billion, a P/E ratio of -36.23 and a beta of 1.96. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 52-week low of $19.16 and a 52-week high of $117.75. The firm's 50 day moving average is $87.10 and its 200 day moving average is $82.61.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.17. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. Analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insider Buying and Selling at GeneDx

In other news, CEO Katherine Stueland sold 2,731 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63. Following the completion of the transaction, the chief executive officer now owns 7,752 shares of the company's stock, valued at approximately $734,346.96. The trade was a 26.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 388 shares of GeneDx stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92. Following the sale, the chief financial officer now owns 3,337 shares in the company, valued at approximately $377,381.33. This represents a 10.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 139,390 shares of company stock valued at $13,043,288 over the last 90 days. 29.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a research note on Friday, May 9th. Wells Fargo & Company reduced their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Guggenheim assumed coverage on shares of GeneDx in a research note on Thursday. They issued a "buy" rating and a $88.00 price target on the stock. The Goldman Sachs Group boosted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Finally, TD Securities reduced their price target on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $86.75.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.